A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment (KOSMOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00772733
Recruitment Status : Completed
First Posted : October 15, 2008
Last Update Posted : February 23, 2011
Information provided by:

Brief Summary:
The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD recommendations. If relevant the general practitioner (GP) will refer patients to COPD rehabilitation conducted by relevant municipality rehabilitation teams. Secondarily the purpose is to improve collaboration and communication between the local hospital pulmonologist, GPs and the municipality rehabilitation team

Condition or disease
COPD Chronic Diseases

Study Type : Observational
Actual Enrollment : 936 participants
Time Perspective: Prospective
Official Title: A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
Study Start Date : October 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Primary Outcome Measures :
  1. Control visits at General practitioners [ Time Frame: 6-12 months ]
  2. Lung function measured by spirometry [ Time Frame: 6-12 months ]

Secondary Outcome Measures :
  1. Dyspnoea on MRC scale [ Time Frame: 6-12 months ]
  2. Smoking status [ Time Frame: 6-12 months ]
  3. Rehabilitation completed in the municipality rehabilitation team [ Time Frame: 6-12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosed patients with COPD, verified by spirometry in general practise and/or municipalities.

Inclusion Criteria:

  • COPD diagnose, verified by spirometry
  • Having given informed consent

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00772733

Research Site
Bjerringbro, Viborg, Denmark
Research Site
Moldrup, Viborg, Denmark
Research Site
Skals, Viborg, Denmark
Research Site
Aalborg, Denmark
Research Site
Arhus, Denmark
Research Site
Klarup, Denmark
Research Site
Orum, Denmark
Research Site
Skive, Denmark
Research Site
Spottrup, Denmark
Research Site
Stoholm, Denmark
Research Site
Viborg, Denmark
Sponsors and Collaborators
Study Chair: Michael Skov Jensen, MD Region Hospital Viborg, DK
Study Chair: Tina Brandt Sorensen, MD Region Hospital Horsens, DK
Principal Investigator: Ove Grann Aalborg

Responsible Party: Björn.E.Eriksson, MD, VP Medical, AstraZeneca Pharmaceuticals Identifier: NCT00772733     History of Changes
Other Study ID Numbers: NIS-RDK-DUM-2007/1
First Posted: October 15, 2008    Key Record Dates
Last Update Posted: February 23, 2011
Last Verified: February 2011

Keywords provided by AstraZeneca:
Quality assurance
chronic care model

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Chronic Disease
Respiratory Tract Diseases
Disease Attributes
Pathologic Processes